TNGX Stock: Price, Earnings History and SEC Filings
Tango Therapeutics, Inc. (TNGX) last traded at $22.72, up 0.84% on the latest session and down 8.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.37 against an analyst estimate of $-0.31, a miss of 19.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TNGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.37 | $-0.31 | -19.35% |
| Mar 2026 | May 13, 2026 | $-0.32 | $-0.32 | +0.00% |
| Dec 2025 | Mar 5, 2026 | $-0.29 | $-0.31 | +6.45% |
| Sep 2025 | Nov 4, 2025 | $0.13 | $0.01 | +1200.00% |
TNGX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How TNGX reacts to earnings
Across its last 8 earnings releases, TNGX moved 10.3% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-11 | Before open | -4.81% |
| 2026-05-13 | After close | -2.51% |
| 2026-03-05 | Before open | +36.28% |
| 2026-01-08 | Before open | -6.23% |
| 2025-11-04 | Before open | +0.00% |
| 2025-10-23 | Before open | -13.05% |
| 2025-08-05 | Before open | +4.86% |
| 2025-05-12 | Before open | +14.91% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TNGX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $62M | -$102M | -$140M | -162.9% | $-0.87 |
| 2024 | $42M | -$130M | -$132M | -309.7% | $-1.19 |
| 2023 | $37M | -$102M | -$120M | -278.5% | $-1.08 |
| 2022 | $25M | -$108M | -$117M | -435.1% | $-1.23 |
| 2021 | $37M | -$58M | -$61M | -157.2% | $-0.94 |
| 2020 | $8M | -$52M | $69M | -678.8% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TNGX
- 8-K · Oct 23, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Aug 11, 2026Other events, Financial statements and exhibits
- 424B5 · Aug 11, 2026
- 8-K · Aug 11, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 11, 2026
- 8-K · Aug 6, 2026Officer or director change
- 8-K · Jun 23, 2026Officer or director change, Financial statements and exhibits
- 8-K · Jun 10, 2026Material agreement, Financial statements and exhibits
- 424B5 · Jun 10, 2026
- 424B5 · Jun 8, 2026
Insider filing activity
TNGX insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TNGX news
- Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In FocusOct 28, 2026 · finance.yahoo.com
- Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is SayingOct 28, 2026 · seekingalpha.com
- Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?Oct 28, 2026 · finance.yahoo.com
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataOct 26, 2026 · finance.yahoo.com
- Tango Therapeutics Highlights Positive Vopimetostat Combination DataOct 24, 2026 · theglobeandmail.com
- Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugOct 23, 2026 · finance.yahoo.com
- Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateOct 23, 2026 · marketbeat.com
- Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?Oct 23, 2026 · finance.yahoo.com
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.